<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493450</url>
  </required_header>
  <id_info>
    <org_study_id>NEMO</org_study_id>
    <nct_id>NCT04493450</nct_id>
  </id_info>
  <brief_title>NEMO - an App for Side Effect Management in Oncology</brief_title>
  <acronym>NEMO</acronym>
  <official_title>NEMO - an App for Side Effect Management in Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Seufferlein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the use of digital and standardized documentation by patients of&#xD;
      frequently occurring adverse events in oncological therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is structured as a Phase I and II clinical trial. In phase I, the&#xD;
      feasibility of using a smartphone application to document adverse events that have occurred&#xD;
      during oncological therapies by the patient will be investigated. In phase II we will&#xD;
      investigate whether the use of the smartphone app allows an improvement of patient care by&#xD;
      reducing occurred adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Phase I: Patient acceptance of a new medium of communication</measure>
    <time_frame>6 months</time_frame>
    <description>Acceptance of documentation of occurring side effects of oncological therapies with new communication media</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Change of occurred adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Changes of side effects by at least 1 degree according to CTCAE scoring in comparison to the study start</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Doses of chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>Maintenance of chemotherapy doses through better adverse event management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Incidence of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of treatment-emergent adverse events as assessed by the CTCAE scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Cancer Patients</condition>
  <arm_group>
    <arm_group_label>Smartphone-users</arm_group_label>
    <description>Cancer patients who use smartphones</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Documentation of cancer treatment side effects</intervention_name>
    <description>Standardized documentation of occurred side effects</description>
    <arm_group_label>Smartphone-users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Phase I:&#xD;
&#xD;
        - 30 participants in total non-randomly divided into three age groups (&lt; 55 years, 55-75&#xD;
        years, &gt; 75 years) of 10 people each.&#xD;
&#xD;
        Phase II:&#xD;
&#xD;
        - 36 participants randomly assigned a group of 18 persons (smartphone users, non-smartphone&#xD;
        users)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  infusional combination therapy with at least two chemotherapy substances with or&#xD;
             without further targeted therapies&#xD;
&#xD;
          -  combination of at least two immune-checkpoint inhibitors&#xD;
&#xD;
          -  able to read and understand German&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded:&#xD;
&#xD;
          -  severe neurological disorders&#xD;
&#xD;
          -  severe psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seufferlein</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
    <phone>+4973150044501</phone>
    <email>thomas.seufferlein@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universit√§tsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Thomas Seufferlein</investigator_full_name>
    <investigator_title>Professor, Head of Department</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

